What is HC Wainwright’s Forecast for MLYS FY2030 Earnings?

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) – Research analysts at HC Wainwright issued their FY2030 earnings estimates for shares of Mineralys Therapeutics in a report issued on Monday, January 26th. HC Wainwright analyst M. Caufield anticipates that the company will post earnings per share of $4.41 for the year. HC Wainwright currently has a “Buy” rating and a $56.00 target price on the stock. The consensus estimate for Mineralys Therapeutics’ current full-year earnings is ($4.23) per share.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.14.

MLYS has been the subject of several other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Thursday, January 22nd. Stifel Nicolaus upped their target price on Mineralys Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Finally, Wells Fargo & Company lifted their price target on Mineralys Therapeutics from $50.00 to $55.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Mineralys Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $47.43.

Mineralys Therapeutics Stock Down 0.6%

NASDAQ MLYS opened at $32.84 on Tuesday. Mineralys Therapeutics has a 52 week low of $8.24 and a 52 week high of $47.65. The firm has a 50 day moving average of $36.74 and a two-hundred day moving average of $32.19. The stock has a market capitalization of $2.60 billion, a PE ratio of -11.13 and a beta of 0.49.

Insider Buying and Selling

In related news, CEO Jon Congleton sold 16,236 shares of the company’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $32.62, for a total transaction of $529,618.32. Following the transaction, the chief executive officer owned 639,151 shares of the company’s stock, valued at $20,849,105.62. This represents a 2.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider David Malcom Rodman sold 11,367 shares of the stock in a transaction on Wednesday, January 14th. The stock was sold at an average price of $32.61, for a total value of $370,677.87. Following the completion of the transaction, the insider owned 50,437 shares of the company’s stock, valued at $1,644,750.57. The trade was a 18.39% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 1,686,955 shares of company stock worth $71,118,551 in the last three months. Company insiders own 33.24% of the company’s stock.

Hedge Funds Weigh In On Mineralys Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in MLYS. Mirae Asset Global Investments Co. Ltd. lifted its stake in Mineralys Therapeutics by 51.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,518 shares of the company’s stock valued at $34,000 after buying an additional 850 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of Mineralys Therapeutics by 198.2% in the third quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company’s stock worth $40,000 after acquiring an additional 676 shares during the last quarter. Ameritas Investment Partners Inc. lifted its position in shares of Mineralys Therapeutics by 42.8% in the second quarter. Ameritas Investment Partners Inc. now owns 3,995 shares of the company’s stock valued at $54,000 after acquiring an additional 1,197 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of Mineralys Therapeutics during the second quarter valued at $91,000. Finally, Russell Investments Group Ltd. increased its position in Mineralys Therapeutics by 14,091.3% during the 3rd quarter. Russell Investments Group Ltd. now owns 3,264 shares of the company’s stock worth $124,000 after purchasing an additional 3,241 shares in the last quarter. 84.46% of the stock is owned by institutional investors and hedge funds.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.